Analyst Ratings for RAPT Therapeutics
Portfolio Pulse from Benzinga Insights
In the last quarter, RAPT Therapeutics (NASDAQ:RAPT) received 7 bullish and 1 somewhat bullish analyst ratings. The company has an average 12-month price target of $40.5, representing a 9.19% decrease from the previous average price target of $44.60.
June 05, 2023 | 3:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RAPT Therapeutics received mostly bullish analyst ratings in the last quarter, with an average 12-month price target of $40.5, down 9.19% from the previous target.
The majority of analyst ratings for RAPT Therapeutics are bullish, indicating a positive outlook for the stock. However, the average 12-month price target has decreased by 9.19%, which may suggest some caution among analysts. The stock price is likely to go up in the short term due to the overall positive sentiment, but the decrease in the price target may limit the potential upside.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100